Drugmaker Sanofi is abandoning two drugs in the late stages of development after trials revealed they weren't more effective than other therapies.
not rated yet |
0
(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.
not rated yet |
0
(HealthDay News) —Prescription drug prices at U.S. pharmacies can vary widely, and failing to shop around could result in people overpaying by as much as $100 or more a month on average, depending on the ...
not rated yet |
0
Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots.
not rated yet |
0
|
The U.S. Justice Department is investigating drug maker Sanofi's disclosures to the Food and Drug Administration about different responses to its blockbuster blood thinner Plavix.
not rated yet |
0
(HealthDay)—In the search for better medicines to safely help heart patients, clinical trials testing three new drugs appear to offer some promise.
4 / 5 (1) |
0
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to ...
5 / 5 (1) |
0
(AP)—Bristol-Myers Squibb Co. and France's Sanofi SA said Wednesday that they are restructuring their longtime partnership selling popular heart medications, now that their sales are plunging due to widespread competition ...
not rated yet |
0
(HealthDay)—A full year of aggressive anti-clotting therapy—which can lead to heavy bleeding—may not be needed after surgery to implant a drug-coated cardiac stent, two new studies suggest.
not rated yet |
0
|
(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.
not rated yet |
0
(HealthDay) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.
not rated yet |
0
Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a ...
not rated yet |
0
|
(HealthDay) -- Aspirin works as well as Plavix in patients with blocked leg arteries, a new European study finds.
5 / 5 (1) |
1
The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according ...
not rated yet |
0
Allergies to Plavix, also know by its chemical name, Clopidogrel occur in about six percent of patients given the drug, vital for the prevention of life-threatening stent thrombosis after angioplasty and percutaneous coronary ...
not rated yet |
0
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix, by Sun Pharmaceuticals under the trade name Clopilet, by Ranbaxy Laboratories under the trade name Ceruvin. It works by irreversibly inhibiting a receptor called P2Y12. Adverse effects include hemorrhage.
This text uses material from Wikipedia licensed under CC BY-SA
